FM
LCTX icon

Family Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Family Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,574
Closed -$34K – 128
2018
Q3 		$34K Sell
16,574
-19,716
-54% -$41.4K 0.02% 69
2018
Q2 		$65K Buy
36,290
+8,572
+31% +$17.3K 0.04% 71
2018
Q1 		$65K Sell
27,718
-9,475
-25% -$22.2K 0.05% 60
2017
Q4 		$70K Sell
37,193
-171,233
-82% -$374K 0.05% 56
2017
Q3 		$518K Buy
208,426
+47,982
+30% +$119K 0.35% 38
2017
Q2 		$442K Buy
160,444
+2,286
+1% +$6.39K 0.3% 39
2017
Q1 		$477K Buy
158,158
+26,713
+20% +$75.9K 0.33% 37
2016
Q4 		$415K Buy
131,445
+32,004
+32% +$98.3K 0.28% 42
2016
Q3 		$339K Sell
99,441
-7,430
-7% -$20.5K 0.19% 55
2016
Q2 		$244K Sell
106,871
-21,717
-17% -$53.3K 0.14% 67
2016
Q1 		$323K Sell
128,588
-4,606
-3% -$10.3K 0.21% 48
2015
Q4 		$441K Sell
133,194
-8,549
-6% -$25.6K 0.23% 53
2015
Q3 		$343K Buy
141,743
+6,195
+5% +$16K 0.15% 72
2015
Q2 		$397K Buy
135,548
+55,012
+68% +$213K 0.16% 66
2015
Q1 		$323K Buy
+80,536
New +$279K 0.15% 63

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Family Management's LCTX Position: Q4 2018 in Review

Family Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2018, closing a stake of 16,574 shares — an estimated $34K sold.

Family Management first reported a position in LCTX in Q1 2015 and held it in 15 quarters. The position peaked at $518K in Q3 2017. 105 funds tracked by Wall St. Rank hold LCTX as of Q4 2018.

  • Family Management reported no remaining Lineage Cell Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Family Management sold 16,574 Lineage Cell Therapeutics shares in Q4 2018, an estimated $34K.
  • Family Management first reported a position in Lineage Cell Therapeutics in Q1 2015 and held it in 15 quarters.
  • Family Management's Lineage Cell Therapeutics position peaked at $518K in Q3 2017.
  • 105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2018.

Based on Family Management's 13F filing for Q4 2018, filed 14 Feb 2019.